^
Association details:
| Biomarker: | EGFR exon 18-25 duplication |
|---|---|
| Cancer: | Non Small Cell Lung Cancer |
| Drug: | erlotinib (EGFR inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Durable response to EGFR tyrosine kinase inhibitors in a patient with non–small cell lung cancer harboring an EGFR kinase domain duplication
Published date:
07/09/2021
Excerpt:
...case of a 45-year-old Japanese woman with NSCLC positive for EGFR-KDD (duplication of exons 18–25) who developed carcinomatous meningitis and showed a marked response to the EGFR-TKIs erlotinib and osimertinib.
DOI:
https://doi.org/10.1111/1759-7714.14081
Test:
